Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Australian scientists develop nasal spray that can stop SARS-CoV-2 infection

Australian scientists develop nasal spray that can stop SARS-CoV-2 infection



As coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to arise globally, scientists are vying to develop an effective drug or vaccine to fight the infection. With more than 33.5 million infected since the beginning of the pandemic in December 2019, finding a cure for those infected is crucial to stopping its spread.

Now, a biotech company in Australia, Ena Respiratory, said the nasal spray it is developing could help boost the human immune system to fight the flu and the common cold, significantly reducing the growth of the coronavirus in a recent animal study.

The potential nasal spray can not only help treat COVID-1

9, but also prevent it.

Nasal spray

The new product, called INNA-051, is being developed by Ena Respiratory, and laboratory experiments show that it reduces viral replication by as much as 96% in an animal study. Led by the Deputy Director of Public Health England (PHE), Professor Miles Carroll, the new study describes the potential treatment and is published on the open source print server. bioRxiv*.

Used as a nasal spray, it aims to boost the body’s natural immune system to fight the common cold and flu. It works by triggering the innate immune system, which is the body’s first line of defense against infection by a pathogen. When the drug improved the immune system, it also prevented SARS-CoV-2 infection and replication in the laboratory.

Clinical observations.  a) Scheme of experimental design.  The ferrets received INNA-051 and PBS treatment 4 days and 1 day before challenge with 5.0 x 106 pfu / ml SARS-CoV-2.  Nasal washes and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 after challenge (pc) for all treatment and control groups.  Planned subtractions were performed for 6/24 ferrets per day 3 pcs and 18/24 ferrets per day 12-14 pc (b) Temperatures were measured twice daily (with approximately 8 hour intervals) using implanted temperature / ID chips .  Average temperatures +/- standard error of the mean (SEM) are displayed.  Temperature drop after SARS-CoV-2 challenge

Clinical observations. a) Scheme of experimental design. The ferrets received INNA-051 and PBS treatment 4 days and 1 day before challenge with 5.0 x 106 pfu / ml SARS-CoV-2. Nasal washes and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 after challenge (pc) for all treatment groups and control group. Planned subtractions were performed for 6/24 ferrets per day 3 pcs and 18/24 ferrets per day 12-14 pc (b) Temperatures were measured twice daily (with approximately 8 hour intervals) using implanted temperature / ID chips . Average temperatures +/- standard error of the mean (SEM) are displayed. Challenge to lower the temperature after SARS-CoV-2

attributed to sedation. (b) The weight shall be recorded daily and a percentage change from the weight of the ferrets shall be plotted before treatment. Mean percentage weight changes +/- SEM are shown.

Clinical observations. a) Scheme of experimental design. The ferrets received INNA-051 and PBS treatment 4 days and 1 day before challenge with 5.0 x 106 pfu / ml SARS-CoV-2. Nasal washes and throat swabs were collected on days 1, 3, 5, 7, 10 and 12 after challenge (pc) for all treatment groups and control group. Planned subtractions were performed for 6/24 ferrets on day 3 and 18/24 ferrets on days 12-14. (B) Temperatures were measured twice daily (approximately 8 hours apart) using implanted temperature / ID chips. Average temperatures +/- standard error of the mean (SEM) are displayed. Challenge to lower the temperature after SARS-CoV-2

attributed to sedation. (b) The weight shall be recorded daily and a percentage change from the weight of the ferrets shall be plotted before treatment. Mean percentage weight changes +/- SEM are shown.

Learning

Respiratory diseases, including those that cause influenza, the common cold, and coronavirus infection, are major ongoing global health threats. These viruses have caused outbreaks of pandemics, threatening the lives of those at higher risk, such as children, the elderly and the immunocompromised.

SARS-CoV-2 infection spreads actively around the world and spreads rapidly from one person to another through close contact and respiratory droplets. One of the biggest threats to the current pandemic is that several people infected with the virus are asymptomatic, meaning they do not know they are carrying the virus. As a result, they are called silent sprinklers.

The research team from the National Infections Service, Public Health England (PHE) wanted to develop a nasal spray to prevent replication of the virus in the nasal area, the most common point of entry of the virus.

To test the nasal spray, the team took nasal washes and a throat swab four days before the viral challenge. After analysis of viral RNA in nasal wash samples, the team confirmed infection in all treatment groups, with lower viral RNA levels observed during treatment with INNA-051.

The team found that prophylactic intranasal administration of INNA-051 in the model of SARS-CoV-2 ferret infection reduced nasal viral RNA levels and the threat.

“The results of our study support the clinical development of therapy based on prophylactic innate immune activation of TLR2 / 6 in URT to reduce SARS-CoV-2 transmission and provide protection against COVID-19,” the team wrote in the article.

In addition, the research team added that the prophylactic approach is important for people at high risk of community transmission or the development of severe COVID-19 disease, such as the elderly, people with comorbidities and immunocompromised.

“We were amazed at how effective our treatment was. By boosting the ferrets’ natural immune response with our treatment, we have seen rapid destruction of the virus, “said Christoph Demison, Managing Director of Ena Respiratory.

“If people react in this way, the benefits of treatment are twofold. People exposed to the virus are likely to eliminate it quickly, and treatment ensures that the disease does not progress beyond mild symptoms. This is especially important for vulnerable members of the community. In addition, the speed of this response means that infected individuals are unlikely to transmit it, which means a rapid cessation of transmission from the community, “he added. https://www.youtube.com/watch?v=AVkjoDG1ZVg

*Important message

bioRxiv

publishes preliminary scientific reports that are not peer-reviewed and therefore should not be considered convincing, guide clinical practice / health-related behavior, or be treated as established information. Source: Magazine reference:


Source link